- FDA Approves Supplemental New Drug Application for Veltassa Removing Boxed Warning Regarding Drug-Drug Interactions
27 November 2016
- FDA Approves Veltassa (patiromer) for Hyperkalemia
21 October 2015
- Relypsa Announces October 21, 2015 as PDUFA Date for NDA for Patiromer for Oral Suspension
5 January 2015
- Relypsa Announces FDA Acceptance of New Drug Application for Patiromer for Oral Suspension to Treat Hyperkalemia
15 December 2014
- Relypsa Submits NDA for Patiromer for Oral Suspension to Treat Hyperkalemia
22 October 2014
Drugs Associated with Vifor Pharma, Inc.
Vifor Pharma, Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.